Asymchem Laboratories Tianjin Co (HKSE:06821) 3-Year EBITDA Growth Rate : 2.70% (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Asymchem Laboratories Tianjin Co 3-Year EBITDA Growth Rate?

Asymchem Laboratories Tianjin Co's EBITDA per Share for the three months ended in Mar. 2025 was HK$1.05.

During the past 12 months, Asymchem Laboratories Tianjin Co's average EBITDA Per Share Growth Rate was -45.40% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 2.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 23.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 26.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Asymchem Laboratories Tianjin Co was 68.80% per year. The lowest was 2.70% per year. And the median was 28.80% per year.

Competitive Comparison of Asymchem Laboratories Tianjin Co's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asymchem Laboratories Tianjin Co's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Asymchem Laboratories Tianjin Co's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Asymchem Laboratories Tianjin Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Asymchem Laboratories Tianjin Co (HKSE:06821) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Asymchem Laboratories Tianjin Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Asymchem Laboratories Tianjin Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Asymchem Laboratories Tianjin Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asymchem Laboratories Tianjin Co Ltd (HKSE:06821) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

7K90:Germany 002821:China

Address

No. 6 Dongting Third Street, Economic and Technological Development Zone, Tianjin, CHN, 300457

Website

https://www.asymchem.com

Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development manufacturing organization solutions throughout the drug development and manufacturing process. The Group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing which focuses on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.

Executives

Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Schroders Plc	2102 Investment manager
Norges Bank	2101 Beneficial owner
Fmr Llc	2201 Interest of corporation controlled by you
Fidelity Investment Trust	2101 Beneficial owner
Springhill Fund Asset Management (hk) Company Limited	2102 Investment manager
Springhill Fund Limited	2201 Interest of corporation controlled by you
Springhill Global Feeder Fund Limited	2201 Interest of corporation controlled by you
Springhill Master Fund Limited	2101 Beneficial owner
Morgan Stanley	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Jpmorgan Asset Management (asia Pacific) Limited	2102 Investment manager
Fidelity Management & Research Company Llc

Asymchem Laboratories Tianjin Co Headlines

No Headlines